Literature DB >> 2023059

In vitro sensitivity assays in cancer: a review, analysis, and prognosis.

R M Hoffman1.   

Abstract

Tumors are complex systems consisting of heterogeneous cancer cells as well as normal cells with each exhibiting unique drug sensitivity spectra. There have been many attempts to design in vitro systems to determine drug response to tumors. The most widely used system is the clonogenic assay. which has demonstrated some clinical predictivity. However, the clonogenic assay has been shown to have negative aspects, including low frequency of evaluation, clump artifacts, lack of cytotoxic end-points and disruption of normal cell-cell interactions existing in a true tissue environment. Newer models are described utilizing cytotoxic as well as cell-proliferation end-points, and maintenance of three-dimensional tissue architecture in vitro. It is concluded that less artifactual, more realistic models can be used to select more tumor-specific drugs which themselves in turn will make in vitro chemosensitivity assays more useful for cancer patients.

Entities:  

Mesh:

Year:  1991        PMID: 2023059     DOI: 10.1002/jcla.1860050211

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  41 in total

1.  Long-term passage of human tissues in vitro as three-dimensional histolines.

Authors:  H K Slocum; K Tòth; L Li; S G Chang; R M Hoffman; Y M Rustum
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

2.  Glucose consumption end point in primary histoculture indicates recovery of human tumors from drug treatment.

Authors:  S G Chang; H K Slocum; K Tòth; R M Hoffman; S D Perrapato; R P Huben; Y Rustum
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

3.  Hair growth in vitro from histocultured skin.

Authors:  L Li; R Paus; L B Margolis; R M Hoffman
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

4.  Targeting antibodies to live tumor tissue in 3-D histoculture.

Authors:  F Guadagni; L Li; R M Hoffman
Journal:  In Vitro Cell Dev Biol       Date:  1992-05

5.  In vivo growth patterns of human lung tumors in three-dimensional histoculture.

Authors:  B Baibakov; G A Frank; N Sergeeva; I Novikova; T Youngkin; K M Connors; R M Hoffman; L B Margolis
Journal:  In Vitro Cell Dev Biol       Date:  1991-12

6.  SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.

Authors:  Claudia C S Chini; Jair M Espindola-Netto; Gourish Mondal; Anatilde M Gonzalez Guerrico; Veronica Nin; Carlos Escande; Mauro Sola-Penna; Jin-San Zhang; Daniel D Billadeau; Eduardo N Chini
Journal:  Clin Cancer Res       Date:  2015-12-11       Impact factor: 12.531

7.  Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice.

Authors:  R A Vescio; K M Connors; T Kubota; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

8.  20-hydroxyvitamin D₃ inhibits proliferation of cancer cells with high efficacy while being non-toxic.

Authors:  Jin Wang; Andrzej Slominski; Robert C Tuckey; Zorica Janjetovic; Anand Kulkarni; Jianjun Chen; Arnold E Postlethwaite; Duane Miller; Wei Li
Journal:  Anticancer Res       Date:  2012-03       Impact factor: 2.480

9.  Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.

Authors:  Kentaro Maejima; Akira Tokunaga; Teruo Kiyama; Hitoshi Kanno; Hideki Bou; Masanori Watanabe; Hideyuki Suzuki; Eiji Uchida
Journal:  Gastric Cancer       Date:  2010-12-03       Impact factor: 7.370

10.  Assay-based response evaluation in head and neck oncology: requirements for better decision making.

Authors:  Andreas Dietz; Andreas Boehm; Iris-Susanne Horn; Pierre Kruber; Ingo Bechmann; Wojciech Golusinski; Dietger Niederwieser; Ralph Dollner; Torsten W Remmerbach; Christian Wittekind; Stephan Dietzsch; Guido Hildebrandt; Gunnar Wichmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.